Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie- associated prion protein accumulation

Journal of Virology

Volumn 74, Issue 10, 2000, Pages 4894-4897

  Doh Ura, Katsumi ^a   Iwaki, Toru ^a   Caughey, Byron ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE PROTEINASE INHIBITOR; PRION PROTEIN;

ARTICLE; NONHUMAN; PRION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; SCRAPIE; VIRUS INHIBITION;

ANIMALS; CYSTEINE PROTEINASE INHIBITORS; INHIBITORY CONCENTRATION 50; LEUCINE; LYSOSOMES; NEUROBLASTOMA; PRPSC PROTEINS; QUINACRINE; TUMOR CELLS, CULTURED;

EID: 0034001444     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.10.4894-4897.2000     Document Type: Article

References (33)

1. Anonymous. 1997. Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts - Japan, January 1979-May 1996. Morbid. Mortal. Weekly Rep. 46:1066-1069.
2. Baricos, W. H., S. E. O'Connor, S. L. Cortez, L. T. Wu, and S. V. Shah. 1988. The cysteine proteinase inhibitor, E-64, reduces proteinuria in an experimental model of glomerulonephritis. Biochem. Biophys. Res. Commun. 155: 1318-1323.
3. Borchelt, D. R., M. Scott, A. Taraboulos, N. Stahl, and S. B. Prusiner. 1990. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J. Cell Biol. 110:743-752.
4. Bruce, M. E., P. A. McBride, and C. F. Farquhar. 1989. Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci. Lett. 102:1-6.
5. Caughey, B., and B. Chesebro. 1997. Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol 7:56-62.
6. Caughey, B., D. Ernst, and R. E. Race. 1993. Congo red inhibition of scrapie agent replication. J. Virol. 67:6270-6272.
7. Caughey, B., and R. E. Race. 1992. Potent inhibition of scrapie-associated PrP accumulation by congo red. J. Neurochem. 59:768-771.
8. Caughey, B., and G. J. Raymond. 1991. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease-and phospholipase-sensitive. J. Biol. Chem. 266:18217-18223.
9. Caughey, B., and G. J. Raymond. 1993. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67:643-650.
10. Caughey, B., G. J. Raymond, D. Ernst, and R. E. Race. 1991. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol. 65:6597-6603.
11. Caughey, W. S., L. D. Raymond, M. Horiuchi, and B. Caughey. 1998. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl. Acad. Sci. USA 95:12117-12122.
12. Chernoff, V. O., S. L. Lindquist, B. Ono, V. S. Inge, and S. W. Liebman. 1995. Role of the chaperone protein Hsp 104 in propagation of the yeast prion-like factor [psi+]. Science 268:880-884.
13. Christensen, B., and R. R. Lullmann. 1988. On the alcianophilia of the drug suramin used as a tool for inducing experimental mucopolysaccharidosis. Histochemistry 89:365-367.
14. Demaimay, R., K. T. Adjou, V. Beringue, S. Demart, C. I. Lasmézas, J.-P. Deslys, M. Seman, and D. Dormont. 1997. Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J. Virol. 71:9685-9689.
15. Ehlers, B., and H. Diringer. 1984. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J. Gen. Virol. 65:1325-1330.
16. Farquhar, C. F., and A. G. Dickinson. 1986. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J. Gen. Virol. 67:463-473.
17. Hein, L., and R. R. Lullmann. 1989. Mucopolysaccharidosis and lipidosis in rats treated with tilorone analogues. Toxicology 58:145-154.
18. Ingrosso, L., A. Ladogana, and M. Pocchiari. 1995. Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. 69:506-508.
19. Jendroska, K., F. P. Heinzel, M. Torchia, L. Stowring, H. A. Kretzschmar, A. Kon, A. Stern, S. B. Prusiner, and S. J. DeArmond. 1991. Proteinase-resistant prion protein accumulation in Syrian hamster brain correlates with regional pathology and scrapie infectivity. Neurology 41:1482-1490.
20. Kimberlin, R. H., and C. A. Walker. 1986. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob. Agents Chemother. 30:409-413.
21. Komatsu, K., K. Inazuki, J. Hosoya, and S. Satoh. 1986. Beneficial effect of new thiol protease inhibitors, epoxide derivatives, on dystrophic mice. Exp. Neurol. 91:23-29.
22. Lullmann-Rauch, R., R. Pods, and B. von Witzendorff. 1996. The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo. Toxicology 110:27-37.
23. McKinley, M. P., A. Taraboulos, L. Kenaga, D. Serban, A. Stieber, S. J. DeArmond, S. B. Prusiner, and N. Gonatas. 1991. Ultrastructural localization of scrapie prion proteins in cytoplasmic vesicles of infected cultured cells. Lab. Investig. 65:622-630.
24. Race, R. E., B. Caughey, K. Graham, D. Ernst, and B. Chesebro. 1988. Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. Virol. 62:2845-2849.
25. Satoyoshi, E. 1992. Therapeutic trials on progressive muscular dystrophy. Intern. Med. 31:841-846.
26. Schneider, P., T. A. Korolenko, and U. Busch. 1997. A review of drug-induced lysosomal disorders of the liver in man and laboratory animals. Microsc. Res. Tech. 36:253-275.
27. Sugita, H., I. Higuchi, M. Sano, and S. Ishiura. 1987. Trial of a cysteine proteinase inhibitor, EST, in experimental chloroquine myopathy in rats. Muscle Nerve 10:516-523.
28. Swietnicki, W., R. Petersen, P. Gambetti, and W. K. Surewicz. 1997. pH-dependent stability and conformation of the recombinant human prion protein PrP(90-231). J. Biol. Chem. 272:27517-27520.
29. Tagliavini, F., R. A. McArthur, B. Canciani, G. Giaccone, M. Porro, M. Bugiani, P. M. Lievens, O. Bugiani, E. Peri, P. Dall'Ara, M. Rocchi, G. Poli, G. Forloni, T. Bandiera, M. Varasi, A. Suarato, P. Cassutti, M. A. Cervini, J. Lansen, M. Salmona, and C. Post. 1997. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 276:1119-1122.
30. Tamai, M., S. Omura, M. Kimura, K. Hanada, and H. Sugita. 1987. Prolongation of life span of dystrophic hamster by cysteine proteinase inhibitor, loxistation (EST). J. Pharmacobio-Dyn. 10:678-681.
31. Will, R. G., J. W. Ironside, M. Zeidler, S. N. Cousens, K. Estibeiro, A. Alperovitch, S. Poser, M. Pocchiari, A. Hofman, and P. G. Smith. 1996. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347:921-925.
32. Yanagishita, M. 1985. Inhibition of intracellular degradation of proteoglycans by leupeptin in rat ovarian granulosa cells. J. Biol. Chem. 260:11075-11082.
33. Zhang, H., J. Stockel, I. Mehlhorn, D. Groth, M. A. Baldwin, S. B. Prusiner, T. L. James, and F. E. Cohen. 1997. Physical studies of conformational plasticity in a recombinant prion protein. Biochemistry 36:3543-3553.